Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Outset Medical ( (OM) ) has provided an update.
On January 27, 2026, Outset Medical announced that the U.S. Food and Drug Administration granted 510(k) clearance for its next-generation Tablo hemodialysis platform, which becomes the first dialysis system to meet the FDA’s most rigorous, recently updated medical device cybersecurity standards. The upgraded Tablo system features enterprise-grade cybersecurity across hardware, software and cloud, modernized operating system and hardware to boost performance and extend maintenance intervals, and a more durable exterior suited to acute hospital environments, with shipments planned to begin in the second quarter of 2026 and existing Tablo customers eligible to upgrade, strengthening the company’s technology lead and value proposition for hospitals, health systems and home dialysis providers.
The most recent analyst rating on (OM) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Outset Medical stock, see the OM Stock Forecast page.
Spark’s Take on OM Stock
According to Spark, TipRanks’ AI Analyst, OM is a Neutral.
The score is held back primarily by continued losses and only moderate cash-flow progress, despite strong trailing revenue growth and sharply improved leverage. Technicals remain mixed with a pressured longer-term trend, and valuation offers limited support given the negative P/E and no dividend. Recent updates (earnings call and preliminary results) show improving margins/cash use, but guidance was lowered and execution risk persists due to sales leadership disruption and deal timing variability.
To see Spark’s full report on OM stock, click here.
More about Outset Medical
Outset Medical, Inc. is a medical technology company focused on transforming the dialysis experience across the continuum of care with its Tablo Hemodialysis System, a first-of-its-kind, FDA-cleared platform for use from hospital to home. Trusted by more than 1,000 U.S. healthcare facilities and used in millions of treatments, Tablo integrates water purification and on-demand dialysate production into a single system that connects with electronic medical records and proprietary analytics, enabling providers to run in-house dialysis programs aimed at improving operational, clinical and financial outcomes in kidney care.
Average Trading Volume: 989,796
Technical Sentiment Signal: Strong Sell
Current Market Cap: $90.12M
For an in-depth examination of OM stock, go to TipRanks’ Overview page.